Cost of achieving HbA1c and weight loss treatment targets with IDegLira vs insulin glargine U100 plus insulin aspart in the USA

References

• International Diabetes FederationIDF diabetes atlas8th ed http://www.diabetesatlas.org/across-the-globe.htmlAccessed November 22, 2017
   Google Scholar
• GreggEWLiYWangJChanges in diabetes-related complications in the United States, 1990–2010N Engl J Med2014370161514152324738668
   PubMed Web of Science ®Google Scholar
• ZhuoXZhangPHoergerTJLifetime direct medical costs of treating type 2 diabetes and diabetic complicationsAm J Prev Med201345325326123953350
   PubMed Web of Science ®Google Scholar
• FoosVVarolNCurtisBHEconomic impact of severe and non-severe hypoglycemia in patients with type 1 and type 2 diabetes in the United StatesJ Med Econ201518642043225629654
   PubMed Web of Science ®Google Scholar
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) GroupLancet199835291318378539742976
   PubMed Web of Science ®Google Scholar
• HolmanRRPaulSKBethelMAMatthewsDRNeilHAW10-year follow-up of intensive glucose control in type 2 diabetesN Engl J Med2008359151577158918784090
   PubMed Web of Science ®Google Scholar
• Ismail-BeigiFCravenTBanerjiMAEffect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trialLancet2010376973941943020594588
   PubMed Web of Science ®Google Scholar
• PatelAMacmahonSChalmersJADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetesN Engl J Med2008358242560257218539916
   PubMed Web of Science ®Google Scholar
• DuckworthWAbrairaCMoritzTVADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetesN Engl J Med2009360212913919092145
   PubMed Web of Science ®Google Scholar
• StettlerCAllemannSJüniPGlycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trialsAm Heart J20061521273816824829
   PubMed Web of Science ®Google Scholar
• TurnbullFMAbrairaCAndersonRJIntensive glucose control and macrovascular outcomes in type 2 diabetesDiabetologia200952112288229819655124
   PubMed Web of Science ®Google Scholar
• MarsoSPDanielsGHBrown-FrandsenKLEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetesN Engl J Med2016375431132227295427
   PubMed Web of Science ®Google Scholar
• ZinmanBWannerCLachinJMEMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetesN Engl J Med2015373222117212826378978
   PubMed Web of Science ®Google Scholar
• InzucchiSEBergenstalRMBuseJBManagement of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care201538114014925538310
   PubMed Web of Science ®Google Scholar
• American Diabetes Association6. Glycemic targetsDiabetes Care201740Suppl 1S48S5627979893
   PubMedGoogle Scholar
• American Diabetes Association7. Obesity management for the treatment of type 2 diabetesDiabetes Care201740Suppl 1S57S6327979894
   PubMedGoogle Scholar
• American Diabetes Association8. Pharmacologic approaches to glycemic treatmentDiabetes Care201740Suppl 1S64S7427979895
   PubMedGoogle Scholar
• WalzLPetterssonBRosenqvistUDeleskogAJournathGWändellPImpact of symptomatic hypoglycemia on medication adherence, patient satisfaction with treatment, and glycemic control in patients with type 2 diabetesPatient Prefer Adherence20148859360124812495
   PubMedGoogle Scholar
• GrandySFoxKMHardyESHIELD Study GroupAssociation of weight loss and medication adherence among adults with type 2 diabetes mellitus: SHIELD (Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes)Curr Ther Res Clin Exp201375778224465048
   PubMedGoogle Scholar
• LimSChoiSHKimKMThe association of rate of weight gain during early adulthood with the prevalence of subclinical coronary artery disease in recently diagnosed type 2 diabetes: the MAXWEL-CAD studyDiabetes Care20143792491249924914242
   PubMedGoogle Scholar
• PieberTRMarsoSPMcguireDKDEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortalityDiabetologia2018611586528913543
   PubMed Web of Science ®Google Scholar
• AbrahamsonMJPetersAIntensification of insulin therapy in patients with type 2 diabetes mellitus: an algorithm for basal-bolus therapyAnn Med201244883684622822902
   PubMed Web of Science ®Google Scholar
• KhuntiKNikolajsenAThorstedBLAndersenMDaviesMJPaulSKClinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulinDiabetes Obes Metab201618440140926743666
   PubMed Web of Science ®Google Scholar
• BillingsLKDoshiAGouetDEfficacy and safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: the DUAL VII randomized clinical trialDiabetes Care20184151009101629483185
   PubMed Web of Science ®Google Scholar
• LangerJHuntBValentineWJEvaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United StatesJ Manag Care Pharm201319323724623537458
   PubMed Web of Science ®Google Scholar
• SkovgaardRJon PlougUHuntBValentineWJEvaluating the cost of bringing people with type 2 diabetes mellitus to multiple targets of treatment in CanadaClin Ther20153781677168826186809
   PubMedGoogle Scholar
• HuntBMocarskiMValentineWJLangerJEvaluation of the short-term cost-effectiveness of IDegLira versus continued up-titration of insulin glargine U100 in patients with type 2 diabetes in the USAAdv Ther201734495496528281218
   PubMed Web of Science ®Google Scholar
• HuntBMcconnachieCCGambleCDang-TanTEvaluating the short-term cost-effectiveness of liraglutide versus lixisenatide in patients with type 2 diabetes in the United StatesJ Med Econ201720111117112028651479
   PubMed Web of Science ®Google Scholar
• LopezJMSMacomsonBEktareVPatelDBottemanMEvaluating drug cost per response with SGLT2 inhibitors in patients with type 2 diabetes mellitusAm Health Drug Benefits20158630931826557225
   PubMedGoogle Scholar
• GarberAJAbrahamsonMJBarzilayJIConsensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2017 executive summaryEndocr Pract201723220723828095040
   PubMed Web of Science ®Google Scholar
• Medi-Span Price Rx Available from: http://www.wolterskluwercdi.com/price-rx/Accessed August 16, 2017
   Google Scholar
• YeawJLeeWCAagrenMChristensenTCost of self-monitoring of blood glucose in the United States among patients on an insulin regimen for diabetesJ Manag Care Pharm2012181213222235952
   PubMedGoogle Scholar
• WeatherallJBloudekLBuchsSBudget impact of treating commercially insured type 1 and type 2 diabetes patients in the United States with insulin degludec compared to insulin glargineCurr Med Res Opin201733223123827764979
   PubMed Web of Science ®Google Scholar
• DempseyMMocarskiMLangerJHuntBLong-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the USJ Med Econ201821111110111830114954
   PubMed Web of Science ®Google Scholar
• DempseyMMocarskiMLangerJHuntBIDegLira is associated with improved short-term clinical outcomes and cost savings compared with insulin glargine U100 plus insulin aspart in the U.SEndocr Pract201824979680430308134
   PubMedGoogle Scholar
• LangerJTianYWengWGambleCMocarskiMAssessing unmet needs for type 2 diabetes patients treated with basal insulin in the United StatesEndocrine Practice201622S27879
   Google Scholar
• LingvayIPérez ManghiFGarcía-HernándezPEffect of insulin glargine up-titration vs insulin Degludec/Liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: the DUAL V randomized clinical trialJAMA2016315989890726934259
   PubMed Web of Science ®Google Scholar
• QaseemAWiltTJKansagaraDHorwitchCBarryMJForcieaMAClinical Guidelines Committee of the American College of PhysiciansHemoglobin A1c targets for glycemic control with pharmacologic therapy for nonpregnant adults with type 2 diabetes mellitus: a guidance statement update from the American College of PhysiciansAnn Intern Med2018168856957629507945
   PubMed Web of Science ®Google Scholar
• TarrideJ-EHopkinsRBlackhouseGA review of methods used in long-term cost-effectiveness models of diabetes mellitus treatmentPharmacoeconomics201028425527720222752
   PubMed Web of Science ®Google Scholar